THERAPEUTIC AGENT OF BLOOD-BRAIN BARRIER DISORDER SYNDROME

Title:

THERAPEUTIC AGENT OF BLOOD-BRAIN BARRIER DISORDER SYNDROME

Document Type and Number:

Japanese Patent JP2015078225

Kind Code:

A

Abstract:

PROBLEM TO BE SOLVED: To provide a pharmaceutical composition for treating or preventing various diseases by enhancing the function of blood-brain barrier.SOLUTION: The pharmaceutical composition contains metformin or buformin which are biguanide drugs, or pharmaceutically acceptable salts thereof as an active ingredient. The pharmaceuticals are used for prevention, suppression, or improvement of tremor, spasm, leukoencephalopathy, headache, sleepiness, disturbance of consciousness, anomalous behavior, delirium, hallucination, delusion, epilepsy, cerebral infarction, hemorrhagic infarct, cerebral edema, brain injury, sepsis, Alzheimer's disease, and diseases selected from combinations thereof. The metformin and buformin are preferred to be hydrochloride and the dosage is preferred to be 125-3000 mg/person/day.

Inventors:

TAKADA FUYUKO
DOGU SHINYA
KATAOKA YASUBUMI
MATSUMOTO JUNICHI
KANESHIMA SHUJI

Application Number:

JP2014255375A

Publication Date:

April 23, 2015

Filing Date:

December 17, 2014

Export Citation:

Click for automatic bibliography generation Help

Assignee:

UNIV FUKUOKA

International Classes:

A61K31/155; A61P9/10; A61P17/02; A61P25/00; A61P25/04; A61P25/08; A61P25/14; A61P25/18; A61P25/26; A61P25/28; A61P31/04

Other References:

JPN6015041498; ＰＬＯＳ　ＯＮＥＶｏｌ．５，　Ｎｏ．３, 201002, ｐ．１-９
JPN6015041495; ＳｔｒｏｋｅＶｏｌ．４１, 201009, ｐ．２６４５-２６５２
JPN6015041497; ＰＮＡＳＶｏｌ．１０７，　Ｎｏ．５０, 2010, ｐ．２１８３０-２１８３５
JPN6016009139; 循環制御Ｖｏｌ．１２，　Ｎｏ．２, 1991, ｐ．２２３-２２８
JPN6016009137; Ｂｉｏｃｈｉｍｉｃａ　ｅｔ　Ｂｉｏｐｈｙｓｉｃａ　ＡｃｔａＶｏｌ．１７８８, 2009, ｐ．８４２-８５７
JPN6015041498; ＰＬＯＳ　ＯＮＥＶｏｌ．５，　Ｎｏ．３, 201002, ｐ．１-９

Attorney, Agent or Firm:

Asamura patent office

Previous Patent: TAIL VARIANT OF OXIDATION-REDUCTION ACTIVITY THERAPEUTIC AGENT FOR THERAPY OF MITOCHONDRIAL DISEASE ...

Next Patent: COMPOSITIONS FOR TREATMENT OR ALLEVIATION OF SKIN DISEASES OR DISORDERS RELATED TO ENHANCED LEVEL OF...